副腎白質ジストロフィー治療薬の世界市場：市場レポート、競合分析、地域別機会 (2025年～2031年)

当レポートは、副腎白質ジストロフィー治療薬 (Adrenoleukodystrophy Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

• 調査範囲
• 市場：タイプ別
  • 世界のタイプ別市場成長: 2020 VS 2024 VS 2031
  • Hormone Replacement
  • Transplant
  • Others
• 市場：用途別
  • 世界の用途別市場シェア: 2020 VS 2024 VS 2031
  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others
• 前提条件と制限
• 調査目的
• 対象期間

第2章 世界の市場成長トレンド

• 世界の副腎白質ジストロフィー治療薬の市場展望 (2020-2031)
• 世界の市場規模：地域別: 2020 VS 2024 VS 2031
• 世界の副腎白質ジストロフィー治療薬の収益市場シェア 地域別 (2020-2025)
• 世界の副腎白質ジストロフィー治療薬の収益予測：地域別 (2026-2031)
• 主要地域と新興市場分析
  • 北米の副腎白質ジストロフィー治療薬 市場規模および予測 (2020-2031)
  • 欧州の副腎白質ジストロフィー治療薬 市場規模および予測 (2020-2031)

第3章 内訳データ：タイプ別

• 世界の副腎白質ジストロフィー治療薬の市場規模実績：タイプ別 (2020-2025)
• 世界の副腎白質ジストロフィー治療薬の市場規模予測：タイプ別 (2026-2031)
• 各種タイプ 副腎白質ジストロフィー治療薬 代表的な企業

第4章 内訳データ：用途別

• 世界の副腎白質ジストロフィー治療薬の市場規模実績：用途別 (2020-2025)
• 世界の副腎白質ジストロフィー治療薬の市場規模予測：用途別 (2026-2031)
• 新たな成長源 副腎白質ジストロフィー治療薬 アプリケーション

第5章 競合他社の状況

• 世界トップ企業 収益
  • 世界の副腎白質ジストロフィー治療薬の上位企業：収益別 (2020-2025)
  • 世界の副腎白質ジストロフィー治療薬の収益シェア：企業別 (2020-2025)
• 世界の企業タイプ別市場シェア (Tier 1, Tier 2, and Tier 3)
• 企業ランキング： 副腎白質ジストロフィー治療薬 収益
• 世界の副腎白質ジストロフィー治療薬 市場集中度分析
  • 世界の副腎白質ジストロフィー治療薬 市場集中度 (CR5 and HHI)
  • 世界の上位10・上位5企業： 副腎白質ジストロフィー治療薬 収益 2024年
• 世界の主要企業 副腎白質ジストロフィー治療薬 本社 および提供地域
• 世界の主要企業 副腎白質ジストロフィー治療薬, 製品およびアプリケーション
• 世界の主要企業 副腎白質ジストロフィー治療薬, 業界参入時期
• M&A, 拡張計画

第6章 地域分析

• 北米の市場: Pレイヤー, セグメントs and 下流
  • 北米の副腎白質ジストロフィー治療薬 企業別収益 (2020-2025)
  • 北米の市場規模：タイプ別
  • 北米の市場規模：用途別
  • 北米の市場 トレンドと機会
• 欧州の市場: Pレイヤー, セグメントs and 下流
  • 欧州の副腎白質ジストロフィー治療薬 企業別収益 (2020-2025)
  • 欧州の市場規模：タイプ別
  • 欧州の市場規模：用途別
  • 欧州の市場 トレンドと機会

第7章 主要企業のプロファイル

• Bluebird Bio
• NeuroVia
• Orpheris
• Minoryx
• MedDay Pharmaceuticals
• Rocket Pharmaceuticals
• Lysogene
• Sangamo Therapeutics

第8章 副腎白質ジストロフィー治療薬 市場動向

• 副腎白質ジストロフィー治療薬 業界動向
• 副腎白質ジストロフィー治療薬 市場の促進要因
• 副腎白質ジストロフィー治療薬 市場の課題
• 副腎白質ジストロフィー治療薬 市場の抑制要因

第9章 市場調査結果と結論

第10章 付録

List of Tables

Table 1. Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Adrenoleukodystrophy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market Adrenoleukodystrophy Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global Adrenoleukodystrophy Drugs Revenue Share by Region (2020-2025)

Table 6. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global Adrenoleukodystrophy Drugs Revenue Share Forecast by Region (2026-2031)

Table 8. Global Adrenoleukodystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2020-2025)

Table 10. Global Adrenoleukodystrophy Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global Adrenoleukodystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2020-2025)

Table 15. Global Adrenoleukodystrophy Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in Adrenoleukodystrophy Drugs Application

Table 18. Global Adrenoleukodystrophy Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Adrenoleukodystrophy Drugs Market Share by Players (2020-2025)

Table 20. Global Top Adrenoleukodystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)

Table 21. Ranking of Global Top Adrenoleukodystrophy Drugs Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Adrenoleukodystrophy Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Adrenoleukodystrophy Drugs, Headquarters and Area Served

Table 24. Global Key Players of Adrenoleukodystrophy Drugs, Product and Application

Table 25. Global Key Players of Adrenoleukodystrophy Drugs, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Adrenoleukodystrophy Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America Adrenoleukodystrophy Drugs Revenue Market Share by Company (2020-2025)

Table 29. North America Adrenoleukodystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America Adrenoleukodystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe Adrenoleukodystrophy Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Company (2020-2025)

Table 33. Europe Adrenoleukodystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe Adrenoleukodystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 35. Bluebird Bio Company Details

Table 36. Bluebird Bio Business Overview

Table 37. Bluebird Bio Adrenoleukodystrophy Drugs Product

Table 38. Bluebird Bio Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 39. Bluebird Bio Recent Development

Table 40. NeuroVia Company Details

Table 41. NeuroVia Business Overview

Table 42. NeuroVia Adrenoleukodystrophy Drugs Product

Table 43. NeuroVia Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 44. NeuroVia Recent Development

Table 45. Orpheris Company Details

Table 46. Orpheris Business Overview

Table 47. Orpheris Adrenoleukodystrophy Drugs Product

Table 48. Orpheris Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 49. Orpheris Recent Development

Table 50. Minoryx Company Details

Table 51. Minoryx Business Overview

Table 52. Minoryx Adrenoleukodystrophy Drugs Product

Table 53. Minoryx Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 54. Minoryx Recent Development

Table 55. MedDay Pharmaceuticals Company Details

Table 56. MedDay Pharmaceuticals Business Overview

Table 57. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product

Table 58. MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 59. MedDay Pharmaceuticals Recent Development

Table 60. Rocket Pharmaceuticals Company Details

Table 61. Rocket Pharmaceuticals Business Overview

Table 62. Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Product

Table 63. Rocket Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 64. Rocket Pharmaceuticals Recent Development

Table 65. Lysogene Company Details

Table 66. Lysogene Business Overview

Table 67. Lysogene Adrenoleukodystrophy Drugs Product

Table 68. Lysogene Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 69. Lysogene Recent Development

Table 70. Sangamo Therapeutics Company Details

Table 71. Sangamo Therapeutics Business Overview

Table 72. Sangamo Therapeutics Adrenoleukodystrophy Drugs Product

Table 73. Sangamo Therapeutics Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)

Table 74. Sangamo Therapeutics Recent Development

Table 75. Adrenoleukodystrophy Drugs Market Trends

Table 76. Adrenoleukodystrophy Drugs Market Drivers

Table 77. Adrenoleukodystrophy Drugs Market Challenges

Table 78. Adrenoleukodystrophy Drugs Market Restraints

Table 79. Research Programs/Design for This Report

Table 80. Key Data Information from Secondary Sources

Table 81. Key Data Information from Primary Sources

List of Figures

Figure 1. Adrenoleukodystrophy Drugs Product Picture

Figure 2. Global Adrenoleukodystrophy Drugs Market Share by Type: 2024 VS 2031

Figure 3. Hormone Replacement Features

Figure 4. Transplant Features

Figure 5. Others Features

Figure 6. Global Adrenoleukodystrophy Drugs Market Share by Application: 2024 VS 2031

Figure 7. Childhood Cerebral ALD

Figure 8. Adrenomyeloneuropathy (AMN)

Figure 9. Addison-only

Figure 10. Others

Figure 11. Adrenoleukodystrophy Drugs Report Years Considered

Figure 12. Global Adrenoleukodystrophy Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Adrenoleukodystrophy Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region: 2020 VS 2024

Figure 15. North America Adrenoleukodystrophy Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. Europe Adrenoleukodystrophy Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. Global Adrenoleukodystrophy Drugs Market Share by Players in 2024

Figure 18. Global Top Adrenoleukodystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2024

Figure 20. North America Adrenoleukodystrophy Drugs Market Share by Type (2020-2025)

Figure 21. North America Adrenoleukodystrophy Drugs Market Share by Application (2020-2025)

Figure 22. Europe Adrenoleukodystrophy Drugs Market Share by Type (2020-2025)

Figure 23. Europe Adrenoleukodystrophy Drugs Market Share by Application (2020-2025)

Figure 24. Bluebird Bio Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 25. NeuroVia Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 26. Orpheris Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 27. Minoryx Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 28. MedDay Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 29. Rocket Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 30. Lysogene Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 31. Sangamo Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)

Figure 32. Bottom-up and Top-down Approaches for This Report

Figure 33. Data Triangulation

Figure 34. Key Executives Interviewed

This research report focuses on the Adrenoleukodystrophy Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market by Type
  • 1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
  • 1.2.2 Hormone Replacement
  • 1.2.3 Transplant
  • 1.2.4 Others
• 1.3 Market by Application
  • 1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
  • 1.3.2 Childhood Cerebral ALD
  • 1.3.3 Adrenomyeloneuropathy (AMN)
  • 1.3.4 Addison-only
  • 1.3.5 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Adrenoleukodystrophy Drugs Market Perspective (2020-2031)
• 2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
• 2.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2020-2025)
• 2.4 Global Adrenoleukodystrophy Drugs Revenue Forecast by Region (2026-2031)
• 2.5 Major Region and Emerging Market Analysis
  • 2.5.1 North America Adrenoleukodystrophy Drugs Market Size and Prospective (2020-2031)
  • 2.5.2 Europe Adrenoleukodystrophy Drugs Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

• 3.1 Global Adrenoleukodystrophy Drugs Historic Market Size by Type (2020-2025)
• 3.2 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Type (2026-2031)
• 3.3 Different Types Adrenoleukodystrophy Drugs Representative Players

4 Breakdown Data by Application

• 4.1 Global Adrenoleukodystrophy Drugs Historic Market Size by Application (2020-2025)
• 4.2 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Application (2026-2031)
• 4.3 New Sources of Growth in Adrenoleukodystrophy Drugs Application

5 Competition Landscape by Players

• 5.1 Global Top Players by Revenue
  • 5.1.1 Global Top Adrenoleukodystrophy Drugs Players by Revenue (2020-2025)
  • 5.1.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Players (2020-2025)
• 5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 5.3 Players Covered: Ranking by Adrenoleukodystrophy Drugs Revenue
• 5.4 Global Adrenoleukodystrophy Drugs Market Concentration Analysis
  • 5.4.1 Global Adrenoleukodystrophy Drugs Market Concentration Ratio (CR5 and HHI)
  • 5.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Drugs Revenue in 2024
• 5.5 Global Key Players of Adrenoleukodystrophy Drugs Head office and Area Served
• 5.6 Global Key Players of Adrenoleukodystrophy Drugs, Product and Application
• 5.7 Global Key Players of Adrenoleukodystrophy Drugs, Date of Enter into This Industry
• 5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

• 6.1 North America Market: Players, Segments and Downstream
  • 6.1.1 North America Adrenoleukodystrophy Drugs Revenue by Company (2020-2025)
  • 6.1.2 North America Market Size by Type
    • 6.1.2.1 North America Adrenoleukodystrophy Drugs Market Size by Type (2020-2025)
    • 6.1.2.2 North America Adrenoleukodystrophy Drugs Market Share by Type (2020-2025)
  • 6.1.3 North America Market Size by Application
    • 6.1.3.1 North America Adrenoleukodystrophy Drugs Market Size by Application (2020-2025)
    • 6.1.3.2 North America Adrenoleukodystrophy Drugs Market Share by Application (2020-2025)
  • 6.1.4 North America Market Trend and Opportunities
• 6.2 Europe Market: Players, Segments and Downstream
  • 6.2.1 Europe Adrenoleukodystrophy Drugs Revenue by Company (2020-2025)
  • 6.2.2 Europe Market Size by Type
    • 6.2.2.1 Europe Adrenoleukodystrophy Drugs Market Size by Type (2020-2025)
    • 6.2.2.2 Europe Adrenoleukodystrophy Drugs Market Share by Type (2020-2025)
  • 6.2.3 Europe Market Size by Application
    • 6.2.3.1 Europe Adrenoleukodystrophy Drugs Market Size by Application (2020-2025)
    • 6.2.3.2 Europe Adrenoleukodystrophy Drugs Market Share by Application (2020-2025)
  • 6.2.4 Europe Market Trend and Opportunities

7 Key Players Profiles

• 7.1 Bluebird Bio
  • 7.1.1 Bluebird Bio Company Details
  • 7.1.2 Bluebird Bio Business Overview
  • 7.1.3 Bluebird Bio Adrenoleukodystrophy Drugs Introduction
  • 7.1.4 Bluebird Bio Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.1.5 Bluebird Bio Recent Development
• 7.2 NeuroVia
  • 7.2.1 NeuroVia Company Details
  • 7.2.2 NeuroVia Business Overview
  • 7.2.3 NeuroVia Adrenoleukodystrophy Drugs Introduction
  • 7.2.4 NeuroVia Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.2.5 NeuroVia Recent Development
• 7.3 Orpheris
  • 7.3.1 Orpheris Company Details
  • 7.3.2 Orpheris Business Overview
  • 7.3.3 Orpheris Adrenoleukodystrophy Drugs Introduction
  • 7.3.4 Orpheris Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.3.5 Orpheris Recent Development
• 7.4 Minoryx
  • 7.4.1 Minoryx Company Details
  • 7.4.2 Minoryx Business Overview
  • 7.4.3 Minoryx Adrenoleukodystrophy Drugs Introduction
  • 7.4.4 Minoryx Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.4.5 Minoryx Recent Development
• 7.5 MedDay Pharmaceuticals
  • 7.5.1 MedDay Pharmaceuticals Company Details
  • 7.5.2 MedDay Pharmaceuticals Business Overview
  • 7.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Introduction
  • 7.5.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.5.5 MedDay Pharmaceuticals Recent Development
• 7.6 Rocket Pharmaceuticals
  • 7.6.1 Rocket Pharmaceuticals Company Details
  • 7.6.2 Rocket Pharmaceuticals Business Overview
  • 7.6.3 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Introduction
  • 7.6.4 Rocket Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.6.5 Rocket Pharmaceuticals Recent Development
• 7.7 Lysogene
  • 7.7.1 Lysogene Company Details
  • 7.7.2 Lysogene Business Overview
  • 7.7.3 Lysogene Adrenoleukodystrophy Drugs Introduction
  • 7.7.4 Lysogene Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.7.5 Lysogene Recent Development
• 7.8 Sangamo Therapeutics
  • 7.8.1 Sangamo Therapeutics Company Details
  • 7.8.2 Sangamo Therapeutics Business Overview
  • 7.8.3 Sangamo Therapeutics Adrenoleukodystrophy Drugs Introduction
  • 7.8.4 Sangamo Therapeutics Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
  • 7.8.5 Sangamo Therapeutics Recent Development

8 Adrenoleukodystrophy Drugs Market Dynamics

• 8.1 Adrenoleukodystrophy Drugs Industry Trends
• 8.2 Adrenoleukodystrophy Drugs Market Drivers
• 8.3 Adrenoleukodystrophy Drugs Market Challenges
• 8.4 Adrenoleukodystrophy Drugs Market Restraints

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer